Intellect Neurosciences, Inc. Issues Letter to Shareholders
GlobeNewswire - Wed Sep 24, 7:00AM CDT
Intellect Neurosciences, Inc. (OTCPNK:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's and other neuro-degenerative diseases today issued the following Letter to Shareholders from Elliot Maza, Chief Executive Officer and CFO.